A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.
To continue reading click here
